🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the bacteria, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are escalating around the world, with data suggesting over 82 million infections annually. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the reality of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options currently available.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts anticipate that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in close succession. This treatment, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to develop it.

“This milestone marks a significant shift in the treatment of highly resistant gonorrhoea, which until now has been staying ahead of antibiotic development.”

Testing Results and Global Access

As per data released by a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The trial enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Clinicians on the front lines have expressed hope. Having a single-dose, oral treatment such as this is described as a "revolutionary step" for public health efforts. This is deemed vital to lessen the impact of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.